Skip to the content
Sinchew Business
  • Home
  • SEAPRWire
  • ACN Newswire
  • JCN Newswire
  • EQS Newswire
  • Contact
JCN Newswire
January 16, 2023

Eisai Files Marketing Authorization Application for Anti-Amyloid-Beta Protofibril Antibody Lecanemab for Early Alzheimer’s Disease in Japan

By sarah

TOKYO and CAMBRIDGE, Mass., Jan 16, 2023 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. and Biogen Inc. announced today that Eisai has submitted a marketing authorization application for lecanemab (Brand Name in the U.S.: LEQEMBI), an investigational anti-amyloid beta (Abeta) protofibril(1) antibody for the treatment of mild cognitive impairment (MCI) due to Alzheimer’s disease (AD) and mild AD dementia (collectively known as early AD) with confirmed presence of amyloid pathology in the brain to the Pharmaceuticals and Medical Devices Agency (PMDA).

This application is based on the results of the Phase III Clarity AD study and Phase IIb clinical study (Study 201), which demonstrated the lecanemab treatment showed a reduction of clinical decline in early AD. Prior to submitting this application, Eisai utilized the prior assessment consultation system of PMDA, with the aim of shortening the review period for lecanemab.

In the Clarity AD study, lecanemab treatment resulted in highly statistically significant results, reducing clinical decline on the global cognitive and functional scale as the primary endpoint (CDR-SB(2): Clinical Dementia Rating-Sum of Boxes) as early as six months, and over time across all time points. All key secondary endpoints also showed highly statistically significant results. Especially, treatment with lecanemab showed a statistically significant reduction in amyloid plaque burden at all timepoints starting at 3 months in the amyloid PET study and statistically significantly slowed decline of activities of daily living on ADCS MCI-ADL(3). The most common adverse events (>10%) in the lecanemab group were infusion reactions, ARIA-H (combined cerebral microhemorrhages, cerebral macrohemorrhages, and superficial siderosis), ARIA-E (edema/effusion), headache, and fall.

In November 2022, the results of Clarity AD study were presented at the 15th Clinical Trials on Alzheimer’s Disease (CTAD) conference and simultaneously published in the peer-reviewed medical journal the New England Journal of Medicine(New Window).

In the U.S., lecanemab was granted accelerated approval as a treatment for AD by the U.S. Food and Drug Administration (FDA) on January 6, 2023. On the same day, Eisai submitted a Supplemental Biologics License Application (sBLA) to the FDA for approval under the traditional pathway. In Europe, Eisai submitted marketing authorization application (MAA) to the European Medicines Agency (EMA) on January 9, 2023. In China, Eisai initiated submission of data for BLA to the National Medical Products Administration (NMPA) of China in December 2022.

Eisai serves as the lead of lecanemab development and regulatory submissions globally with both Eisai and Biogen co-commercializing and co-promoting the product and Eisai having final decision-making authority.

This release discusses investigational uses of an agent in development and is not intended to convey conclusions about efficacy or safety. There is no guarantee that such an investigational agent will successfully gain health authority approval.

For more information, visit www.eisai.com/news/2023/news202307.html.

MEDIA CONTACT:
Eisai Co., Ltd.
Public Relations Department
TEL: +81-(0)3-3817-5120

Eisai Inc. (U.S.)
Libby Holman
+ 1-201-753-1945
Libby_Holman@eisai.com

INVESTOR CONTACT:
Eisai Co., Ltd.
Investor Relations Department
TEL: +81-(0)03-3817-5122

Copyright 2023 JCN Newswire. All rights reserved. (via SEAPRWire)

Tagsapplication lecanemab study submitted treatment

Post navigation

Previous PostPrevious MHI Signs MoU to Collaborate in Feasibility Studies on Ammonia Co-Firing for Power Generation in BLCP Power Station
Next PostNext Coinbase and GenTwo Digital announce partnership for custody and execution

Categories

  • ACN Newswire
  • EQS Newswire
  • JCN Newswire
  • SEAPRWire

Sinchew News

  • Toyota Tsusho, IIJ, NEC, and NTT Com Sign Contract with Uzbektelecom for Telecommunications Infrastructure Development Project January 27, 2023
  • Eisai: Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer’s Disease Accepted by European Medicines Agency January 27, 2023
  • SCIB Enforces Rights to Withdraw from Project January 27, 2023
  • TMC Announces Changes to Executive Structure January 27, 2023
  • Eccentric Engine launches Virtual Retail Cloud at NADA 2023 January 27, 2023
  • Nippon Steel, Mitsubishi Corporation and ExxonMobil to Evaluate and Establish CCS Value Chains in the Asia Pacific Region January 26, 2023
  • Kurita Water Industries and Hitachi Launch a Co-creation to Implement Solution in Society and Build an Ecosystem for a Sustainable Society with “Zero Environmental Impact” January 26, 2023
  • Four Companies Announce Joint Feasibility Study of Large-Scale and Wide-Area Carbon Capture and Storage (CCS) Value Chain Project Using Ship Transportation January 26, 2023
  • Mitsubishi Power Receives Order for H-25 Gas Turbine for Taiwan’s Chang Chun Petrochemical January 26, 2023
  • Palladium One Initiates 2023 Exploration Program and Expands the Tyko Nickel – Copper Project, Canada January 26, 2023
  • As Mentor by eDriving Passes 3.5 Billion Miles Driven, Analysis Confirms Program’s Ability to Reduce Risky Driving Behaviors January 26, 2023
  • Fujitsu and Mizuho Bank embark on collaboration for sustainable management information services January 26, 2023
  • Cantor Fitzgerald首次覆盖 普瑞健康予“增持”评级 January 26, 2023
  • Cantor Fitzgerald Initiates Coverage on Prenetics with “Overweight” Rating January 26, 2023
  • Mastering Wind Power Online Workshop is Back by Popular Demand January 26, 2023

Pages

  • About Us
  • Contact Us
  • Term of Use

Links

  • YAHOO
  • NASDAQ
  • Bloomberg
  • Newswire
  • EastMud
  • AsiaEase
  • NetDace
  • PostVN
  • VOASG
  • EventPH
Copyright © 2020 Sinchewbusiness.Com